[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572255":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":45,"locations":18,"responsibleParty":50,"collaborators":52,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":18,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":82,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":18},{"fullName":5,"class":6},"National Cancer Center, Korea","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SDM Group (Shared Decision-Making Group; Intervention Group)","EXPERIMENTAL","* Patients will receive detailed information, including an information leaflet about treatment options.\n* Clinicians will guide patients through a structured SDM protocol before finalizing the treatment decision.",[13],"Other: SDM protocol",{"label":15,"type":16,"description":17,"interventionNames":18},"SC Group (Standard Care Group; Control Group)","NO_INTERVENTION","\\- Patients will receive standard medical care following current clinical practices without the SDM protocol.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"OTHER","SDM protocol","Card news and Videos related to general knowledge and treatment of low-risk thyroid cancer",[9],[26,30,33,36,39,42],{"name":27,"affiliation":28,"role":29},"Young Joo Park","Seoul National University Hospital","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":29},"Eun Kyung Lee","National Cancer Center",{"name":34,"affiliation":35,"role":29},"Min Joo Kim","Seoul National University Bundang Hospital",{"name":37,"affiliation":38,"role":29},"Young Shin Song","SMC-SNU Boramae Medical Center",{"name":40,"affiliation":41,"role":29},"Kyong Yeun Jung","Nowon Eulji Medical Center",{"name":43,"affiliation":44,"role":29},"Shin Je Moon","Hanyang University",[46],{"name":31,"role":47,"phone":48,"phoneExt":18,"email":49},"CONTACT","+82-31-920-1743","eklee@ncc.re.kr",{"type":51,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[53,54,55,57,58],{"name":28,"class":21},{"name":35,"class":21},{"name":56,"class":21},"SMG-SNU Boramae Medical Center",{"name":41,"class":21},{"name":44,"class":21},"100572255","shared-decision-making-for-determining-treatment-strategies-in-low-risk-thyroid-cancer-100572255",false,"NCT06730893","Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer","Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: a Multicenter Cluster-Randomized Controlled Trial","MAeSTro-SDM","Inclusion Criteria:\n\n* Adults aged 18 years or older with a thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.\n* Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).\n\nExclusion Criteria:\n\n* Patients who cannot undergo regular follow-up or are expected to have difficulties with follow-up.\n* Patients with indeterminate or benign findings on thyroid biopsy.","ALL","18 Years",{"count":70,"type":71},310,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study is a multicenter cluster-randomized controlled trial conducted in Korea. A parallel, two-group cluster-randomized design will be used to test whether the Shared decision-making Group (SDM; intervention) is different from the Standard Care Group (SC; control).",[77,78],"Thyroid Cancer","Papillary Thyroid Carcinoma",[80,81],"Active surveillance","Shared decision making","NOT_YET_RECRUITING","2025-04-27",{"date":85,"type":86},"2025-04-30","ACTUAL",{"date":88,"type":71},"2025-05-12",{"date":90,"type":71},"2027-12-31",{"name":5,"class":6}]